

Karolinska Development portfolio company Aprea Therapeutics enrolls first patients in Phase II trial of APR-246 in ovarian cancer

STOCKHOLM, SWEDEN – October 10, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Aprea Therapeutics AB announced today that it enrolled the first patients in the Phase II part of the ongoing PiSARRO clinical study of APR-246 for the treatment of high-grade serous ovarian cancer.

Details from the Aprea announcement follow:

“The initiation of the Phase II clinical study marks an important milestone for Aprea,” said Christian S. Schade, President and Chief Executive Officer of Aprea Therapeutics AB. “We are committed to developing and advancing therapies targeting p53 and, together with upcoming clinical studies of APR-246 in other tumor types, this Phase II study in ovarian cancer affirms the progress Aprea is making toward the development of next-generation anticancer treatments.”

In the Phase II clinical study, Aprea will enroll up to 400 relapsed, p53-mutated high-grade serous ovarian cancer patients in Europe and the United States. Patients will be randomized between carboplatin and pegylated liposomal doxorubicin with or without APR-246; the primary endpoint for the study is progression-free survival. This study follows successful completion of Phase Ib clinical studies showing that APR-246 is generally well-tolerated while showing robust signals of efficacy in patients with serious disease.

Dr. Mikael von Euler, Aprea’s Senior Vice President and Chief Medical Officer added, “APR-246 is an exciting new agent because it targets tumors with mutant forms of p53, the gene most frequently altered in human cancers. The Phase Ib portion of this study demonstrated not only that APR-246 can be safely combined with standard chemotherapy for relapsed ovarian cancer but also that a favorable impact on progression-free survival could be achieved with the combination regimen in this difficult-to-treat population. We are pleased to continue development of this drug candidate and look forward to validating these Phase Ib findings in the randomized Phase II part of the study.”

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com

Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk

For Aprea Therapeutics

Christian S. Schade, President and Chief Executive Officer
chris.schade@aprea.com

Gregory A. Korb, Ph.D., Vice President of Business Development
greg.korb@aprea.com

TO THE EDITORS

About p53 and APR-246

The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumors. These mutations are often associated with resistance to anticancer drugs and poor overall survival, representing a major unmet medical need in the treatment of cancer.

APR-246 has been shown to reactivate mutant p53 protein – by reconvert mutant p53 into wild-type p53 conformation and function – and thereby induce programmed cell death in human cancer cells. APR-246 has demonstrated compelling pre-clinical antitumor activity in a wide variety of solid and hematological (blood) tumors, including ovarian cancer, small cell lung cancer, esophageal cancer and AML (acute myeloid leukemia), among others. Additionally, strong synergy has been seen with both traditional anticancer agents, such as chemotherapy, as well as newer mechanism-based anticancer drugs. In addition to pre-clinical testing, a Phase I clinical study has been completed, demonstrating a favorable safety profile and both biological and clinical responses in hematological tumors with mutations in the p53 gene. The Company is also expecting to begin additional clinical studies of APR-246 in other cancer indications.

Safety and efficacy data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II clinical study of APR-246 in relapsed high-grade serous ovarian cancer was presented at the 2016 annual meeting of the European Society for Medical Oncology. The Phase Ib part of the clinical study included 28 patients, in a 3+3 dose escalation design of APR-246 (35, 50 and 67.5 mg/kg intravenously over 6 hours on days 1-4) in combination with carboplatin AUC 5 and PLD 30 mg/m² given on day 4 of a 28-day schedule. Treatment was continued to a maximum of 6 cycles, demonstrating a favorable safety profile and encouraging clinical responses. Of 22 patients with radiologically measurable lesions, 3 had confirmed complete response, 10 had confirmed partial response, 8 had stable disease and 1 was not evaluable. Additionally, of 2 patients with non-measurable disease, 1 had complete response and 1 had progressive disease. Median progression free survival for 22 evaluable patients was 316 days (95% CI 280-414 days), similar for partially platinum-sensitive and platinum-sensitive patients, and was independent of the dose-cohort.

About Aprea Therapeutics AB

Aprea Therapeutics AB is a Boston, Massachusetts- and Stockholm, Sweden-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein, p53. The Company's lead program, APR-246, a first-in-class small molecule drug candidate, is in Phase Ib/II clinical development in ovarian cancer patients, and additional clinical studies with APR-246 in other cancer indications are planned. In March 2016, Aprea completed a EUR 46 million Series B financing with an international syndicate co-led by Versant Ventures and 5AM Ventures, with additional participation by Sectoral Asset Management, HealthCap, acting as local lead investor, and existing investor, Karolinska Development. For more information, please visit www.apreatherapeutics.com.

About Karolinska Development AB

Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients' lives and provide an attractive return on investment.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of 10 companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com